KEPEMRY Trademark

Trademark Overview


On Monday, July 30, 2018, a trademark application was filed for KEPEMRY with the United States Patent and Trademark Office. The USPTO has given the KEPEMRY trademark a serial number of 88057423. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 28, 2022. This trademark is owned by Eli Lilly and Company. The KEPEMRY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
kepemry

General Information


Serial Number88057423
Word MarkKEPEMRY
Filing DateMonday, July 30, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 28, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 25, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 3, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, March 28, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 28, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, July 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 19, 2021EXTENSION 5 GRANTED
Thursday, July 15, 2021EXTENSION 5 FILED
Thursday, July 15, 2021TEAS EXTENSION RECEIVED
Thursday, January 21, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 19, 2021EXTENSION 4 GRANTED
Tuesday, January 19, 2021EXTENSION 4 FILED
Tuesday, January 19, 2021TEAS EXTENSION RECEIVED
Tuesday, August 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, August 8, 2020EXTENSION 3 GRANTED
Monday, July 20, 2020EXTENSION 3 FILED
Saturday, August 8, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 20, 2020TEAS EXTENSION RECEIVED
Tuesday, January 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 17, 2020EXTENSION 2 GRANTED
Friday, January 17, 2020EXTENSION 2 FILED
Friday, January 17, 2020TEAS EXTENSION RECEIVED
Thursday, July 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 16, 2019EXTENSION 1 GRANTED
Tuesday, July 16, 2019EXTENSION 1 FILED
Tuesday, July 16, 2019TEAS EXTENSION RECEIVED
Tuesday, February 19, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 25, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 25, 2018PUBLISHED FOR OPPOSITION
Wednesday, December 5, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 16, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 16, 2018ASSIGNED TO EXAMINER
Friday, August 3, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 2, 2018NEW APPLICATION ENTERED IN TRAM